Abstract: The present invention relates to newly identified seven-transmembrane proteins, including proteins that function as receptors belonging to the superfamily of G-protein-coupled receptors. The invention also relates to polynucleotides encoding the seven-transmembrane proteins/receptors. The invention further relates to methods using the seven-transmembrane protein/receptor polypeptides and polynucleotides as a target for diagnosis and treatment in seven-transmembrane protein/receptor-mediated and related disorders. The invention further relates to drug-screening methods using the seven-transmembrane protein/receptor polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the seven-transmembrane protein/receptor polypeptides and polynucleotides. The invention further relates to procedures for producing the receptor polypeptides and polynucleotides.

Abstract: The invention relates to OCT-3 polypeptides, nucleic acid molecules encoding OCT-3, and uses thereof. OCT-3 is a protein that is expressed in the plasma membrane of biological cells, across which it regulates the transport of organic molecules.

Abstract: The present invention relates to methods for the diagnosis and treatment of pain or painful disorders. Specifically, the present invention identifies the differential expression of 1465, 1587, 2146, 2207, 32838, 336 OR 52908 genes in tissues relating to pain sensation, relative to their expression in normal, or non-painful disease states, and/or in response to manipulations relevant to pain. The present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating pain or painful disorders. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of pain and painful disorders.

Abstract: The present invention relates to methods for the diagnosis and treatment of pain or painful disorders. Specifically, the present invention identifies the differential expression of 577, 20739 OR 57145 genes in tissues relating to pain sensation, relative to their expression in normal, or non-painful disease states, and/or in response to manipulations relevant to pain. The present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating pain or painful disorders. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of pain and painful disorders.

Abstract: The present invention relates to methods for the diagnosis and treatment of a urological disorder or urological disorders. Specifically, the present invention identifies the differential expression of 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 and 6351 genes in tissues relating to urological disorders, relative to their expression in normal, or non-urological disorders, and/or in response to manipulations relevant to a urological disorder. The present invention describes methods for the diagnostic evaluation and prognosis of various urological disorders, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating a urological disorder or urological disorders. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of urological disorders.

Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of pain disorders. The invention further provides methods for identifying a compound capable of treating a pain disorder. In addition, the invention provides a method for treating a subject having a pain disorder characterized by aberrant 57749 polypeptide activity or aberrant 57749 nucleic acid expression.

Abstract: The invention provides isolated nucleic acids molecules, designated 20716, 65494, 44576, 1983, 52881, 2398, 45449, 50289, 52872, 22105, 22109, 22108, 47916, 33395, 31939, and 84241 nucleic acid molecules, which encode novel G protein-coupled receptor family members, human thioredoxin family members, human leucine-rich repeat family members, and human ringfinger family member. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 20716, 65494, 44576, 1983, 52881, 2398, 45449, 50289, 52872, 22105, 22109, 22108, 47916, 33395, 31939, or 84241 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 20716, 65494, 44576, 1983, 52881, 2398, 45449, 50289, 52872, 22105, 22109, 22108, 47916, 33395, 31939, or 84241 gene has been introduced or disrupted.

Abstract: The invention provides isolated nucleic acids molecules, designated 5433 nucleic acid molecules, which encode calcium channel family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 5433 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 5433 gene has been introduced or disrupted. The invention still further provides isolated 5433 proteins, fusion proteins, antigenic peptides and anti-5433 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

Abstract: The invention provides isolated nucleic acids molecules, designated 43238 nucleic acid molecules, which encode novel G-protein coupled receptor family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 43238 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 43238 gene has been introduced or disrupted. The invention still further provides isolated 43238 proteins, fusion proteins, antigenic peptides and anti-43238 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

Abstract: Novel GPCR-like polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length GPCR-like proteins, the invention further provides isolated GPCR-like fusion proteins, antigenic peptides, and anti-GPCR-like antibodies. The invention also provides GPCR-like nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a GPCR-like gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.

Abstract: The present invention relates to methods for the diagnosis and treatment of a urological disorder or urological disorders. Specifically, the present invention identifies the differential expression of 313, 333, 5464, 18817 or 33524 genes in tissues relating to urological disorder, relative to their expression in normal, or non-urological disorder disease states, and/or in response to manipulations relevant to a urological disorder. The present invention describes methods for the diagnostic evaluation and prognosis of various urological diseases, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating a urological disorder or urological disorders. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of urological disorders.

Abstract: The invention relates to OCT-3 polypeptides, nucleic acid molecules encoding OCT-3, and uses thereof. OCT-3 is a protein that is expressed in the plasma membrane of biological cells, across which it regulates the transport of organic molecules.

Abstract: Isolated nucleic acids molecules, designated 33751 nucleic acid molecules, which encode a human potassium channel family member, are disclosed. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33751 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33751 gene has been introduced or disrupted. Isolated 33751 proteins, fusion proteins, antigenic peptides and anti-33751 antibodies are also disclosed. The invention provides, inter alia, methods of modulating 33751 activity or expression, thereby modulating pain or nociceptive responses in a subject. The invention further provides methods of treating, preventing and diagnosing neural disorders.

Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of pain disorders, including, but not limited to, inflammatory pain, chronic pain and/or neuropathic pain. The invention further provides methods for identifying a compound capable of treating a pain disorder or modulating pain and/or inflammation. The invention further provides a method for modulating pain and/or inflammation in a subject. In addition, the invention provides a method for treating a subject having a pain disorder characterized by aberrant 2047 polypeptide activity or aberrant 2047 nucleic acid expression.

Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of pain disorders, including, but not limited to, inflammatory pain, chronic pain and/or neuropathic pain. The invention further provides methods for identifying a compound capable of treating a pain disorder or modulating pain and/or inflammation response. The invention further provides a method for modulating pain and/or inflammation in a subject. In addition, the invention provides a method for treating a subject having a pain disorder characterized by aberrant 46566 polypeptide activity or aberrant 46566 nucleic acid expression.

Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of pain disorders. The invention further provides methods for identifying a compound capable of treating a pain disorder. In addition, the invention provides a method for treating a subject having a pain disorder, e.g., a pain disorder characterized by aberrant 9805 polypeptide activity or aberrant 9805 nucleic acid expression.

Abstract: The invention provides isolated nucleic acids molecules, designated 1983, 52881, 2398, 45449, 50289, and 52872 nucleic acid molecules, which encode novel G protein-coupled receptor members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 1983, 52881, 2398, 45449, 50289, or 52872 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 1983, 52881, 2398, 45449, 50289, or 52872 gene has been introduced or disrupted. The invention still further provides isolated 1983, 52881, 2398, 45449, 50289, or 52872 proteins, fusion proteins, antigenic peptides and anti-1983, 52881, 2398, 45449, 50289, or 52872 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

Abstract: The present invention relates to newly identified human transporters. In particular, the invention relates to transporter polypeptides and polynucleotides, methods of detecting the transporter polypeptides and polynucleotides, and methods of diagnosing and treating transporter-related disorders. Also provided are vectors, host cells, and recombinant methods for making and using the novel molecules.

Abstract: The invention provides isolated nucleic acids molecules, designated 2466 nucleic acid molecules, which encode a G protein coupled receptor family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 2466 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 2466 gene has been introduced or disrupted. The invention still further provides isolated 2466 proteins, fusion proteins, antigenic peptides and anti-2466 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

Abstract: The invention provides isolated nucleic acids molecules, designated 87144 nucleic acid molecules, which encode novel amino acid transporter family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 87144 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 87144 gene has been introduced or disrupted. The invention still further provides isolated 87144 proteins, fusion proteins, antigenic peptides and anti-87144 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.